Kyverna Therapeutics (NASDAQ: KYTX) net income
Kyverna Therapeutics reported a net loss of $161.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $127.5m. Earnings per share were −$3.64.
Kyverna Therapeutics's best year of the last 3 was fiscal 2023. It reported a loss in 3 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$161.3m | — | — | −$3.64 |
| 2024 | −$127.5m | — | — | −$3.33 |
| 2023 | −$60.4m | — | — | −$89.61 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Kyverna Therapeutics net income compared with its sector
By net income for its latest fiscal year, Kyverna Therapeutics ranks 389th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 387th | Editas Medicine | −$160.1m | −395.0% |
| 388th | CG Oncology | −$161.0m | −3,985.0% |
| 389th | Kyverna Therapeutics | −$161.3m | — |
| 390th | Dianthus Therapeutics | −$162.3m | −1,007.1% |
| 391st | Olema Pharmaceuticals | −$162.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Kyverna Therapeutics
- How much did Kyverna Therapeutics earn in fiscal 2025?
- Kyverna Therapeutics reported a net loss of $161.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $127.5m.
- What are the earnings per share of Kyverna Therapeutics?
- They were −$3.64 in fiscal 2025, compared with −$3.33 in fiscal 2024.
- Where does Kyverna Therapeutics rank in its sector by net income?
- It ranks 389th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Kyverna Therapeutics come from?
- From the annual report (Form 10-K) that Kyverna Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Kyverna Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Kyverna Therapeutics: the Kyverna Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.